Search PubMed⌕ Search

Biomedical subjects

T D Moon

Publications and source records attributed to T D Moon.

53 records · Page 3Linked to original sources
PubMed1988

The effect of opiates upon prostatic carcinoma cell growth.

The effect of opiate receptor agonists upon cell growth of the prostatic carcinoma cell line DU145 were studied. Dynorphin-A increased growth significantly with a peak response at 10(-13) M, of 21 +/- 4% (mean +/- SEM). The dose response curve had a typical inverted-U shape. Dynorphin fragments 1-13 and 1-7 also increased growth at 10(-13) M, while the 2-13 fragment failed to increase growth. Naloxone increased growth at high concentration (10(-7) M) suggesting a stimulatory effect, while at the same time blocking the effect of dynorphin-A. This data demonstrates that agents which stimulate opiate receptors, especially the kappa receptor agonist dynorphin, increase the growth of prostatic carcinoma, and that this effect is controlled by changes at the N-terminal end of the peptide. This effect is blocked by Naloxone.

Cell Division↗
PubMed1988

Malacoplakia of the urethra.

We report a case of urethral malacoplakia associated with disease of the bladder and bladder neck. Treatment consisted of fulguration of the bladder lesions and excision of the urethral lesion. Unlike most other cases of genitourinary malacoplakia, which are associated with chronic urinary tract infection, this patient had sterile urine and no history of urinary tract infections. Urethral malacoplakia is reviewed, and the pathogenesis and treatment of the disease are discussed.

Female↗
PubMed1986

Radiation therapy as adjuvant treatment after radical prostatectomy: patient tolerance and preliminary results.

For the last 7 years we administered therapeutic doses of radiation therapy as adjuvant treatment after radical prostatectomy in 45 patients at high risk for recurrence, that is patients with pathological stage C (seminal vesicle invasion) or stage D1a (microscopic involvement of the resected pelvic lymph nodes) disease. All of the patients have been followed for at least 2 years. Short-term and long-term complications were minimal; only 2 patients had significant sequelae that were managed satisfactorily. There has been no local recurrence after mean followups of 62 and 48 months for patients with stages C and D1a disease, respectively. The actuarial 5-year survival rate free of disease was 79 per cent for patients with stage C and 72 per cent with stage D1a cancer.

Carcinoma↗
PubMed1986

Transurethral resection of the prostate with local anesthesia in 100 patients.

We performed transurethral resections of the prostate in 100 patients under local anesthesia supplemented when appropriate by intravenous medication. In the first part of the study (40 patients) local anesthesia was infiltrated into the prostate transurethrally only, while in the second part (60 patients) infiltration was performed transurethrally and perineally. Prostate sizes ranged from 5 to 50 gm., and pain control was excellent in the majority of the patients, especially when perineal infiltration was added to the procedure. Of the patients 98 per cent said they would do it again, no patient required conversion to general anesthesia and there were no significant complications relating to the anesthesia. Local anesthesia with intravenous supplementation can be performed successfully in the majority of the patients with small to moderately sized prostate glands.

Aged↗
PubMed1985

A highly restricted antigen for renal cell carcinoma defined by a monoclonal antibody.

Monoclonal antibodies against renal cell carcinoma (RCC) antigens were generated by immunizing Balb/c mice with the human RCC cell line 7860. After cloning many RCC reactive monoclonal antibodies, one antibody (D5D), was of special interest. Specificity testing against 33 human tumor cell lines revealed D5D to have no specific reactivity with 17 specimens of normal adult or fetal kidney. Reactivity with 67 specimens of nonrenal tissue demonstrated no reactivity. The reactivity of D5D with 15 different RCC tissues has been variable, being present in 60% of cases. Preliminary data, however, suggest that the antigen may be reexpressed for some of the remaining 40% during in vitro propagation.

Antibodies, Monoclonal↗
PubMed1985

Monoclonal antibodies to human renal cell carcinoma: recognition of shared and restricted tissue antigens.

Monoclonal antibodies (MABs) reactive with human renal cell carcinoma (RCC) were generated following immunization of mice with either RCC homogenates, RCC cell lines, or fetal kidney homogenates. The characteristics of four highly reactive immunoglobulin G1 MABs, designated UMVA-RCC-A6H, UMVA-RCC-A36, UMVA-RCC-C5H and UMVA-RCC-D5D are presented. The screening process consisted of a cell binding enzyme-linked immunosorbent assay and immunohistological examination of tumor, normal, and fetal tissue sections. The MABs illustrated various degrees of antigen restriction: A6H identified an antigen common to RCC, some lung and colon carcinomas, the proximal renal tubules but no other normal tissues; A36 reacted with most human tumors, the renal tubules, and many other normal tissues; C5H reacted with nearly every human cancer but of the normal tissues, only the renal glomerulus shared this antigen; D5D was very restrictive, reacting with many although not all RCC and no other cancers or normal tissues with the exception of an occasional reactivity with a Bowman's capsule. Metastatic RCC and RCC xenografts expressed these antigens. None of the MABs participated in complement-mediated cytotoxicity. In immunoprecipitation studies with L-[methyl-3H]methionine and [3H]glucosamine-HCl metabolically labeled RCC cells, C5H was shown to be associated with an antigen of Mr 115,000.

Animals↗
PubMed1985

Monoclonal antibodies in human renal cell carcinoma and their use in radioimmune localization and therapy of tumor xenografts.

A series of monoclonal antibodies (Mabs) to human renal cell carcinoma (RCC) material was developed. Two Mabs (D5D and A6H) that showed especially restrictive reactivities were radiolabeled with iodine 131 and tested in nude mice bearing human tumor xenografts for their ability to specifically localize RCC. Extensive studies of tissue radioactive uptake indicated that these Mabs could specifically localize RCC tumors with some mice achieving high tumor:blood ratios ranging from 15 to 60. Scintigraphic scanning revealed specific and consistent detection of RCC xenografts. Finally, preliminary results indicate that larger intravenous doses of radiolabeled RCC Mabs were effective as radioimmune therapy in inhibiting RCC xenograft growth. Mabs can be produced that are highly restrictive to human RCC and may be useful clinically for radioimmunoscintigraphy or therapy.

Animals↗
PubMed1983

The role of calmodulin in human renal cell carcinoma.

Calmodulin is a ubiquitous intracellular calcium binding protein which has been shown to be associated with cell cycling. Previous studies using animal tumor models have suggested a positive correlation between tumor calmodulin content and rate of tumor growth. We studied the role of calmodulin in renal cell carcinoma (RCC) cell lines and compared this with short term normal fetal kidney cell lines. The effects of calmodulin inhibition was determined using the calmodulin inhibitor W13 (Naphthalene-sulfonamide) and its less active partner W12. Cell size, calmodulin content and inhibition studies using W13 did not reveal any simple correlations for the RCC cell lines, although the RCC lines did have a higher content than the fetal kidney cell lines. Calmodulin content determination of RCC and normal adult kidney tissue failed to show any difference. We conclude that, contrary to previous reports using animal models, there is no simple relationship between tumor growth rates and calmodulin content for human RCC.

Adenocarcinoma↗
PubMed1983

Synchronous independent primary osteosarcoma and adenocarcinoma of kidney.

Primary osteogenic sarcomas are extremely rare tumors of the kidney. The association with a juxtaposed renal "clear" cell carcinoma would appear to be unique, although several cases of osteogenic sarcomatous differentiation have been described within so-called sarcomatoid renal cell carcinoma variants. We report a case of synchronous independent development of both renal cell carcinoma and osteogenic sarcoma within the same kidney.

Adenocarcinoma↗
PubMed1983

Acid phosphatase for monitoring prostatic carcinoma. Comparison of radioimmunoassay and enzymatic techniques.

We compared a commercial radioimmunoassay kit with an enzymatic assay for prostatic acid phosphatase in monitoring the progression or remission of disease in 27 patients with prostatic cancer. In 5 of the 18 patients whose disease progressed, and in 4 of the 9 whose disease responded to treatment, the change was reflected better by the radioimmunoassay. In no case was the enzymatic assay better. Radioimmunoassay for prostatic acid phosphatase may be an effective and sensitive way to monitor the course of carcinoma of the prostate.

Acid Phosphatase↗
PubMed1983

Monoclonal antibodies in urology.

The recent development of hybridoma technology has made it possible to obtain large quantities of antibody against a single determinant (monoclonal antibodies). This review describes the history of hybridoma technology and the method of producing monoclonal antibodies. It examines the role of such antibodies in diagnosis, tissue typing, histochemistry, developmental biology and study and treatment of diseases, including cancer, emphasizing the work being done on urological diseases.

Animals↗
PubMed1983

The role of calmodulin in human natural killer cell activity.

Calcium is known to play an essential role in the lytic mechanism of natural killer cells (NK), which form a subset of large granular lymphocytes. Many of the intracellular effects of calcium are mediated through the calcium-binding protein calmodulin. In this study we have demonstrated that the specific calmodulin inhibitors (naphthalene-sulphonamides) inhibit NK activity in humans at IC50's of 6.9 microM for W7 and 5.2 microM for W13. Comparison of the potency of these compounds with their less active counterparts suggests that NK activity is calmodulin-dependent.

Calmodulin↗
PubMedDate not supplied

CT angiography of potential renal transplant donors.

Renal transplantation has grown rapidly over the past 30 years, resulting in an inadequate supply of organs to meet the ever-increasing demand. This has led to an increase in the number of living-related donors. Advances in imaging technology now allow safe, rapid, and relatively noninvasive evaluation of potential donors. Helical computed tomographic (CT) angiography is a fast, minimally invasive procedure that is quickly becoming the imaging modality of choice for preoperative evaluation of potential renal transplant donors. Helical CT, combined with low-osmolar intravenous contrast materials, has enabled CT angiography to depict arterial and venous anatomy accurately. Between July 1995 and March 1997, CT angiography was performed in 205 potential renal donors. Correlation with surgical findings in 136 donor nephrectomies helped confirm a high level of accuracy for CT angiography in the assessment of the renal vasculature: Sensitivity and specificity for identifying specific vessels was 99.6% and 99.6% for main renal arteries, 76.9% and 89.9% for polar arteries, and 98.7% and 95.5% for main renal veins, respectively. CT angiography allows the radiologist to provide the transplant surgeon with precise preoperative anatomy of the renal vasculature, thus reducing the risks and complications associated with the harvesting procedure and improving the chances for a successful outcome. However, accurate radiologic interpretation depends on the radiologist's experience level, attention to detail, and commitment to careful image evaluation.

Angiography↗